Malignant tumor
Conditions
Interventions
SCART group:Innovative Stereotactic Body External Radiation Therapy Group: The dose level is 21Gy delivered in 3 fractions, while maintaining a margin dose of 5Gy per fraction around the entire tumor
Control group:Radiotherapy will be delivered using external beam radiation, employing 2D/conventional techniques, 3D conformal therapy, intensity-modulated radiation therapy (IMRT), stereotactic radio
Sponsors
Foshan Fosun Chancheng Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patient has been pathologically confirmed to have cancer through tumor biopsy. 2. The patient is diagnosed with stage IV cancer according to the American Joint Committee on Cancer (AJCC) 7th edition, with a minimum size of 5cm at the largest cross-sectional area. 3. One or more metastatic lesions (not site-specific). Metastatic lesions are counted as follows: lesions are counted by different organs (including satellite nodules). 4. The patient has non-stage IV cancer, but with tumor dimensions of 5cm in any continuous dimension, is not considered a surgical candidate and is not suitable for final chemotherapy. 5. The patient has an ECOG performance status of = 18 years old. 8. The patient has signed an informed consent form. 9. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier methods; abstinence) during the study and for six (6) months after discontinuing the study drug. Women of childbearing potential are defined as those who have had a menstrual period in the past 12 months and have not undergone tubal ligation, hysterectomy, or bilateral oophorectomy. If a woman becomes pregnant or suspects she is pregnant during her participation in this study, she should notify her attending physician immediately. If the patient is male, he agrees to use effective contraception or abstinence during the study and for six (6) months after discontinuing the study drug.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of uncontrolled angina, arrhythmias, or congestive heart failure. 2. Patients with a history of malignant pleural effusion are ineligible.Researchers hold the view that pleural effusion which is too small to perform diagnostic thoracentesis is permissible. 3. Patients who are pregnant (if applicable, confirmed by serum b-HCG) or lactating. 4. Patients must not have any comorbid conditions with a life expectancy of <= 6 months, or any uncontrolled intermittent diseases, including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, or any psychiatric disorders/social situations that would limit compliance with study requirements. 5. Exclusion of patients with brain metastases from enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Blood routine test;C-reactive protein(CRP);Lactate Dehydrogenase;T cells, B cells, and Natural Killer cells (CD3\CD4\CD8\CD19\NK); | — |
Secondary
| Measure | Time frame |
|---|---|
| Th1/Th2 cytokines (IL2/IL4/IL6/IL10); | — |
Countries
China
Contacts
Public ContactYang Jun
Foshan Fosun Chancheng Hospital
Outcome results
None listed